
MAT-GB-ENZ-2025-00002 April 2026
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00182 December 2025
MAT-GB-ENZ-2025-00002 April 2026
Enzalutamide is indicated for the treatment of adult men with:
*Defined as prostate specific antigen (PSA) doubling time ≤ 9 months, with PSA ≥1 ng/ml post-prostatectomy (+/- radiotherapy) or ≥2 ng/ml above nadir post-radiotherapy only.
**Defined as baseline prostate-specific antigen (PSA) ≥2 ng/mL and PSA doubling time ≤10 months.1
Reference 1. Enzalutamide SmPC
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Astellas Pharma Ltd. on 0800 783 5018.